In a recent livestream discussion with Dr. Ken Berry, researcher and educator Dr. Nick Norwitz tackled a medical dilemma that has been quietly haunting a growing segment of the low-carb and carnivore dieting community. For many individuals adopting high-fat, animal-based diets, the initial results are often dramatic: energy levels soar and excess weight drops off. However, that early triumph frequently hits a roadblock during routine medical checkups when a physician observes a low-density lipoprotein (LDL) cholesterol reading of 250 or 300 milligrams per deciliter, immediately reaching for the statin prescription pad.
The debate surrounding these elevated numbers has been heavily fueled by two brand-new papers making waves in the scientific community. One study suggests that individuals with sky-high apolipoprotein B (apoB) levels might occasionally defy textbook risk predictions under specific metabolic conditions, while the other spotlights a rare genetic mutation that can aggressively clog arteries even when a patient’s cholesterol markers look completely normal. These findings have left many wondering how clinicians should approach cardiovascular risk assessment moving forward.
According to Dr. Norwitz, the answer requires far more nuance than either side of the ongoing ideological cholesterol wars is often willing to admit.
The Big Takeaway: Context Rewrites the Meaning of LDL
The central message from these recent studies is not a blanket recommendation to ignore your cholesterol levels. Instead, both papers emphasize that a single isolated biomarker value carries very little clinical meaning when viewed entirely divorced from its surrounding metabolic picture. Dr. Norwitz urges patients to question default medical reactions rather than automatically swearing off necessary pharmaceutical interventions. A comprehensive approach—incorporating advanced imaging, broader metabolic markers, and deeper clinical conversations—must belong in the evaluation of cardiovascular health.
Paper One: When HDL Is High, apoB Seems to Lose Its Grip
The first piece of research, an extensive analysis led by prominent lipidologist Dr. Alan Sniderman and published in the European Journal of Preventive Cardiology, examined data from roughly 293,000 participants. Dr. Norwitz highlighted a key takeaway from the data: when high-density lipoprotein (HDL) cholesterol is elevated, the traditional statistical effect of changing apoB levels appears to vanish. The study’s authors even floated the hypothesis that this phenomenon might help explain the apparent clinical immunity observed in some individuals who maintain very high LDL and apoB levels without experiencing adverse cardiovascular events.
When examining the graphical data from the paper, researchers observed that as HDL levels climb, overall population risk trends downward. Simultaneously, the statistical slope mapping apoB against risk flattens out from a steep incline to almost horizontal. Dr. Norwitz noted that the lower threshold line in the cohort, situated at two standard deviations above the mean, sat around 84 milligrams per deciliter—a figure that rests remarkably close to the threshold typically seen in lean mass hyper-responders on ketogenic diets.
However, Dr. Norwitz was quick to emphasize important limitations. The participants in this massive observational cohort were not carnivore dieters; they were everyday people whose biomarkers simply fell within certain statistical ranges. He cautioned that having an HDL level just above 84 milligrams per deciliter does not automatically grant immunity to the atherogenic potential of high apoB. Because observational data can only reveal population patterns rather than definitively prove individual cause and effect, the standard apoB-risk relationship still slopes upward for the vast majority of the population.
Causality Is Not Importance
To clarify how clinicians should view these varying markers, Dr. Norwitz argued that LDL and apoB frequently hog the medical spotlight simply because they are considered causal factors and are relatively easy to lower with existing medications. Yet, he pointed out that establishing causality does not automatically equate to being the single most important variable in a complex biological system.
Using an illustrative analogy, he noted that oxygen is strictly causal to a fire, yet depleting all the oxygen in an environment to prevent a fire would simply result in suffocation. HDL, by contrast, functions more like a litmus test for overall metabolic health rather than a direct mechanical lever to pull. Even so, he cautioned that extremely high HDL levels can stem from wildly different underlying causes, ranging from pristine lean metabolic health to heavy alcohol consumption.
Paper Two: The "Guardian of the Artery"
The second study, published in the high-profile journal Cell, centers on an immunoregulatory gene known as GIMAP6. Dr. Norwitz colloquially nicknamed its associated protein the "guardian of the artery." When researchers knocked out this gene in animal models, the aortas filled rapidly with inflammatory immune cells and developed structural leakiness, despite the animals maintaining completely normal cholesterol levels.
Human beings carrying specific mutations in this pathway also exhibit perfectly normal conventional cholesterol panels yet develop premature cardiovascular disease and face early mortality. Dr. Norwitz pointed to data from the UK Biobank demonstrating a staggering odds ratio near eight for atherosclerosis when evaluated on a logarithmic scale.
His interpretation of these findings is that vascular leakiness and localized inflammation can often precede actual plaque accumulation. This sequence challenges the classic "response-to-retention" model of heart disease, which traditionally posits that circulating LDL particles simply drift passively into the arterial wall and seed the entire disease process. While this specific genetic mutation is rare and serves primarily to illustrate the sheer power of inflammation rather than entirely disproving the well-documented role of LDL, the practical clinical lesson remains straightforward: keeping systemic and arterial inflammation under strict control is paramount.
Should Anyone Still Consider a Statin?
Addressing the clinical utility of pharmaceutical interventions, Dr. Norwitz offered a balanced perspective by steel-manning the conventional medical view. For individuals presenting with low HDL levels and compromised overall metabolic health, the statistical slope relating apoB to cardiovascular risk is exceptionally steep. In such cases, intervention carries a much clearer rationale.
Furthermore, modern statin medications perform functions that extend beyond merely lowering circulating LDL particles. They have been shown to help reduce arterial inflammation and support endothelial nitric oxide production. When a patient’s arteries are actively inflamed, these pleiotropic effects can carry significant clinical weight.
At the individual level, Dr. Norwitz advises patients to be deeply thoughtful rather than blindly extrapolating broad population statistics onto their personal biology. He also pointed to a 2024 study published in Cell Metabolism involving 40 individuals, which observed that a statin prescription lowered GLP-1 levels by roughly 50 percent over a 16-week period. While this was a small trial and does not constitute definitive proof of clinical harm, he argues that the subtle molecular impacts of pharmaceutical drugs deserve far more rigorous attention in modern cardiology.
Imaging Beats the Forecast
Reflecting on diagnostic strategies, both hosts emphasized that relying solely on routine blood lipid numbers is akin to looking at a weather forecast. By contrast, advanced cardiac imaging is equivalent to simply stepping outside to check if rain is actually falling. Direct visualization allows a patient and their physician to look inside the coronary arteries and determine whether atherosclerotic plaque is physically present, an assessment that will always surpass the predictive power of any single biomarker alone.
When navigating these complex discussions with a healthcare provider, Dr. Norwitz suggests approaching appointments with genuine curiosity rather than an antagonistic mindset. How a practitioner responds to nuanced, curious inquiries serves as a reliable litmus test for whether they are genuinely interested in a collaborative therapeutic relationship or simply relying on standard protocols.
Ultimately, when a patient encounters a physician who reacts defensively or dismissively to questions regarding advanced lipid subfractions and metabolic context, Dr. Norwitz offered a direct verdict. While many conventional physicians sincerely believe they are acting in their patients’ best interests and handing over total control is a completely valid choice for individuals who prefer absolute reliance on professional judgment, those seeking a true clinical partnership should seek out a practitioner who treats them like an active collaborator rather than an object to be manipulated.
